QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
The lifetime risk of an unexpected and sudden death from a cardiovascular cause in the absence of pre-existing heart disease—known as sudden cardiac death—is more than 4 times higher for people with ...
The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
Among the mothers, Auger's group found that HS was associated with a threefold higher risk of infection (HR 3.37, 95% CI 2.86 ...
Nodenza Venture Partners launchedFocus on international early-stage and pre-commercial biotech & medtech opportunitiesNew York, October 16, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback